A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 266, 173-181
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 22 references indexed in Scilit:
- Efficacy and Safety of Desvenlafaxine 50 mg/d for Prevention of Relapse in Major Depressive DisorderThe Journal of Clinical Psychiatry, 2013
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trialDepression and Anxiety, 2010
- Desvenlafaxine for the Prevention of Relapse in Major Depressive DisorderJournal of Clinical Psychopharmacology, 2010
- Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey InitiativeDepression and Anxiety, 2009
- Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment DiscontinuationThe Journal of Clinical Psychiatry, 2008
- Ethnicity/Race and Outcome in the Treatment of DepressionMedical Care, 2007
- Escitalopram Maintenance Treatment for Prevention of Recurrent DepressionThe Journal of Clinical Psychiatry, 2006
- Duloxetine in the prevention of relapse of major depressive disorderThe British Journal of Psychiatry, 2006
- Multiple Recurrences of Major Depressive DisorderAmerican Journal of Psychiatry, 2000